NCT06519747 DETECTion of PeriOperative Atrial Fibrillation After Noncardiac Surgery
| NCT ID | NCT06519747 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Population Health Research Institute |
| Condition | Atrial Fibrillation |
| Study Type | OBSERVATIONAL |
| Enrollment | 750 participants |
| Start Date | 2024-10-15 |
| Primary Completion | 2026-08-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 750 participants in total. It began in 2024-10-15 with a primary completion date of 2026-08-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multicentre prospective cohort study where patients will receive up to 14 days of continuous ECG monitoring by wearing a portable monitoring device, starting within 72 hours after noncardiac surgery.
Eligibility Criteria
Inclusion Criteria: 1. Had undergone noncardiac surgery within the past 72 hours and requiring, or expected to require, at least one of the following: * an overnight hospital admission after surgery * day surgery that would result in a large enough physiological insult to be able to cause POAF. Procedures excluded include those that are conducted using local anesthesia alone, are less than 30 minutes in duration, and/or are judged to be of low physiologic insult by the local investigator. 2. Have one of the following high-risk criteria; * age 55-64 years, and having either established cardiovascular disease, recent major vascular surgery, a CHA2DS2-VASc score ≥3, or an elevated postoperative troponin level; * age 65-74 years, and having either established cardiovascular disease, recent major vascular surgery, a CHA2DS2-VASc score ≥2, or an elevated postoperative troponin level; or * age ≥75 years; 3. Provide written informed consent to participate. Exclusion Criteria: 1. History of documented chronic (i.e., non-transient) AF before noncardiac surgery; 2. Need for long-term systemic anticoagulation; 3. Ongoing need for long-term dual antiplatelet treatment; 4. Contraindication to oral anticoagulation; 5. Severe renal insufficiency; 6. Severe liver cirrhosis; 7. Acute stroke in the past 14 days; 8. Underwent cardiac surgery in the past 35 days; 9. History of nontraumatic intracranial, intraocular, or spinal bleeding; 10. Hemorrhagic disorder or bleeding diathesis; 11. Known life expectancy \<1 year due to concomitant disease; 12. Women who are pregnant, breastfeeding, or of childbearing potential not taking effective contraception; 13. Expected to be non-compliant with follow-up and/or device use; 14. Known contact allergy to monitoring device and/or its peripheral components; 15. Previously enrolled in DETECT-POAF.
Contact & Investigator
David Conen, MD, MPH
PRINCIPAL INVESTIGATOR
Population Health Research Institute
Frequently Asked Questions
Who can join the NCT06519747 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 120 Years, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06519747 currently recruiting?
Yes, NCT06519747 is actively recruiting participants. Contact the research team at detectpoaf@phri.ca for enrollment information.
Where is the NCT06519747 trial being conducted?
This trial is being conducted at Hamilton, Canada, Hamilton, Canada, Hamilton, Canada, London, Canada and 2 additional locations.
Who is sponsoring the NCT06519747 clinical trial?
NCT06519747 is sponsored by Population Health Research Institute. The principal investigator is David Conen, MD, MPH at Population Health Research Institute. The trial plans to enroll 750 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.